Drawing for TIME IS BRAIN

USPTO serial 78793870

TIME IS BRAIN

Reviewed by CopyMark Law Group

Reg. 3297427Status 710
Filing date
Status date
Registration date
Sep 25, 2007
Examiner
MUNSON OTT, MARY DEIRDRE
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with TIME IS BRAIN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Gary D. Krugman

GARY D KRUGMAN SUGHRUE MION PLLC2100 PENNSYLVANIA AVE NWSUITE 800WASHINGTON, DC 20037-3200

Goods and services

ClassDescriptionStatusFirst use
001Reagents for scientific or medical research use; diagnostic preparations or reagents for scientific or research use, biochemical reagents for scientific or medical research use; biochemical diagnostic preparations or reagents for scientific or research useSECTION 8 - CANCELLED—
005Pharmaceutical preparations, namely, pharmaceutical preparations derived from living organism proteins and peptides for treatment and diagnosis of strokes, neuron damage, thrombotic diseases, tumors, cancer, heart disease including heart failure, circulation disorders, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; pharmaceutical anti-inflammatory preparations; pharmaceutical nutriceutical preparations for the treatment of strokes, neuron damage, thrombotic diseases, tumors, cancer, heart disease including heart failure, circulation disorders, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; pharmaceutical preparations, namely, thrombolytic, fibrinolytic anti-coagulative, antithrombotical or neuroprotective substances for the treatment of blood clotting, cell protection and cell regeneration; products from biotechnological methods, namely, proteins fortherapeutic and diagnostic use in the treatment and diagnosis of blood clotting disorders; blood clotting test kits comprised of medical diagnostic reagents; medical and clinical diagnostic reagents for clinical or medical laboratory useSECTION 8 - CANCELLED—
010Laboratory devices for medical and pharmaceutical investigations, namely, portable medical devices for conducting medical diagnostic tests and blood specimen analysis of the human blood clotting system; medical devices, namely, coated catheters, medical stents, surgical implants comprising artificial materials; membranes intended for medical use, namely, filters for dialysis, hemofiltrationSECTION 8 - CANCELLED—
035Computerized database management, namely, editing, evaluating and processing data for third parties; performance of pre-clinical studies, namely, managing pre-clinical trials and studies of pharmaceutical, bio-technology and health care productsSECTION 8 - CANCELLED—
041Educational services, namely, providing seminars, informational events and/or workshops in the field of biotechnology, pharmacology, biochemistry, molecular biology, medical procedures, product research and development of medical devices and pharmaceutical preparations, research procedures, protein design diagnostics, molecular diagnostics, proteogenomic profiling, gendiagnosticsSECTION 8 - CANCELLED—
042Database development for others; computer programming for others; performing chemical analyses for others; technical consultation in the field of biotechnology; licensing of intellectual property; services of a biotechnological laboratory, namely, conducting lab research for others in the field of drug research and development; pharmaceutical consulting, namely, providing pharmaceutical advice to others regarding governmental regulatory laws and practices, performing pre-clinical studies, quality control; preparation of expert opinions in the field of chemical engineering, biology, molecular biology, pharmacology, chemistry, bio-technology, bio-chemistry, product research and development of medical devices and pharmaceutical preparations, and molecular diagnostic services of a bio-chemist, namely, product research and development services for others in the area of protein identification, design and development, gene expression analysis, namely, proteogenomic profiling, DNA-sequencing, drug target development and identifying, designing and analyzing therapeutic proteins; diagnostic services in the field of molecular science, comparative genome analysis, DNA-arrays including DNA-microarrays, creation of nucleic acid libraries, screening of nucleic acid libraries; performance of pre-clinical studies, namely, conducting pre-clinical trials and studies of pharmaceutical, bio-technology and health care products; bio-chemical and biotechnological research and development for others, namely, bio-technological research and development regarding medical disease diagnosis and pharmacology, namely, prenatal diagnostic and identification of hereditary factors leading to diseases, identification of genes involved in the formation of cancer, identification of target molecules for cancer treatment; scientific research on and development of medical diagnostic equipment and pharmaceutical preparations and products for the treatment of stroke, neuron damage, thrombotic diseases, tumors, cancer, heart diseases including heart failure, circulation disorders, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; scientific and technical consulting for others in the field of medical science and drug research, namely, identifying, designing, and developing drugs, specifically, therapeutic proteins, gene expression analysis, namely, proteogenomic profiling, DNA-sequencing, drug target development, identification and design; medical science research services for others, namely, prenatal diagnostics, molecular diagnostics, comparative genome analysis, DNA-arrays including DNA-microarrays, creating and screening of nucleic acid libraries, identifying hereditary factors leading to diseases, identifying genes involved in the formation of cancer, identification of target molecules for cancer treatmentSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 2, 2014C8..CANCELLED SEC. 8 (6-YR)—
Sep 25, 2007R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 10, 2007PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 20, 2007NPUBNOTICE OF PUBLICATION—
May 1, 2007PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
May 1, 2007CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 27, 2007XAECEXAMINER'S AMENDMENT ENTERED—
Apr 27, 2007GNEAEXAMINERS AMENDMENT E-MAILED—
Apr 27, 2007CNEAEXAMINERS AMENDMENT -WRITTEN—
Feb 2, 2007GNSLLETTER OF SUSPENSION E-MAILED—
Feb 2, 2007CNSLSUSPENSION LETTER WRITTEN—
Jan 31, 2007ACECAMENDMENT FROM APPLICANT ENTERED—
Jan 31, 2007CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 31, 2007ALIEASSIGNED TO LIE—
Jan 5, 2007MAILPAPER RECEIVED—
Jul 10, 2006GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 10, 2006CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 7, 2006DOCKASSIGNED TO EXAMINER—
Mar 22, 2006AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
Mar 22, 2006MAILPAPER RECEIVED—
Jan 24, 2006NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance